JP2004532877A - 治療に有効なニコチン性アセチルコリン受容体に対する新規なリガンド - Google Patents

治療に有効なニコチン性アセチルコリン受容体に対する新規なリガンド Download PDF

Info

Publication number
JP2004532877A
JP2004532877A JP2003500091A JP2003500091A JP2004532877A JP 2004532877 A JP2004532877 A JP 2004532877A JP 2003500091 A JP2003500091 A JP 2003500091A JP 2003500091 A JP2003500091 A JP 2003500091A JP 2004532877 A JP2004532877 A JP 2004532877A
Authority
JP
Japan
Prior art keywords
disorder
disease
deficits
treating
compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2003500091A
Other languages
English (en)
Japanese (ja)
Other versions
JP2004532877A5 (cg-RX-API-DMAC7.html
Inventor
アイフィーオン・フィリップス
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
AstraZeneca AB
Original Assignee
AstraZeneca AB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by AstraZeneca AB filed Critical AstraZeneca AB
Publication of JP2004532877A publication Critical patent/JP2004532877A/ja
Publication of JP2004532877A5 publication Critical patent/JP2004532877A5/ja
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/22—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains four or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/02—Antidotes

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Toxicology (AREA)
  • Pain & Pain Management (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Anesthesiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
JP2003500091A 2001-06-01 2002-05-29 治療に有効なニコチン性アセチルコリン受容体に対する新規なリガンド Pending JP2004532877A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US29520601P 2001-06-01 2001-06-01
PCT/SE2002/001031 WO2002096912A1 (en) 2001-06-01 2002-05-29 Novel ligand for nicotinic acetylcholine receptors useful in therapy

Publications (2)

Publication Number Publication Date
JP2004532877A true JP2004532877A (ja) 2004-10-28
JP2004532877A5 JP2004532877A5 (cg-RX-API-DMAC7.html) 2006-01-05

Family

ID=23136711

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2003500091A Pending JP2004532877A (ja) 2001-06-01 2002-05-29 治療に有効なニコチン性アセチルコリン受容体に対する新規なリガンド

Country Status (18)

Country Link
EP (1) EP1397366B1 (cg-RX-API-DMAC7.html)
JP (1) JP2004532877A (cg-RX-API-DMAC7.html)
KR (1) KR20040003021A (cg-RX-API-DMAC7.html)
CN (1) CN1294136C (cg-RX-API-DMAC7.html)
AT (1) ATE353332T1 (cg-RX-API-DMAC7.html)
BR (1) BR0210075A (cg-RX-API-DMAC7.html)
CA (1) CA2455341A1 (cg-RX-API-DMAC7.html)
DE (1) DE60218032T2 (cg-RX-API-DMAC7.html)
DK (1) DK1397366T3 (cg-RX-API-DMAC7.html)
ES (1) ES2280538T3 (cg-RX-API-DMAC7.html)
IL (1) IL158735A0 (cg-RX-API-DMAC7.html)
MX (1) MXPA03010996A (cg-RX-API-DMAC7.html)
NO (1) NO20035333D0 (cg-RX-API-DMAC7.html)
NZ (1) NZ529426A (cg-RX-API-DMAC7.html)
PT (1) PT1397366E (cg-RX-API-DMAC7.html)
SI (1) SI1397366T1 (cg-RX-API-DMAC7.html)
WO (1) WO2002096912A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA200308779B (cg-RX-API-DMAC7.html)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10164139A1 (de) 2001-12-27 2003-07-10 Bayer Ag 2-Heteroarylcarbonsäureamide
US7417050B2 (en) 2002-04-18 2008-08-26 Astrazeneca Ab Heterocyclic compounds
KR20040099448A (ko) * 2002-04-18 2004-11-26 아스트라제네카 아베 티에닐 화합물
EP1499618B1 (en) 2002-04-18 2010-10-13 AstraZeneca AB Furyl compounds
KR20060094962A (ko) * 2003-10-21 2006-08-30 아스트라제네카 아베 스피로푸로피리딘 아릴 유도체
TW200813067A (en) * 2006-05-17 2008-03-16 Astrazeneca Ab Nicotinic acetylcholine receptor ligands
SA08290475B1 (ar) 2007-08-02 2013-06-22 Targacept Inc (2s، 3r)-n-(2-((3-بيردينيل)ميثيل)-1-آزا بيسيكلو[2، 2، 2]أوكت-3-يل)بنزو فيوران-2-كربوكساميد، وصور أملاحه الجديدة وطرق استخدامه
HRP20130234T1 (hr) 2008-06-20 2013-04-30 Astrazeneca Ab Derivat dibenzotiazepina i njegova uporaba
TW201031664A (en) 2009-01-26 2010-09-01 Targacept Inc Preparation and therapeutic applications of (2S,3R)-N-2-((3-pyridinyl)methyl)-1-azabicyclo[2.2.2]oct-3-yl)-3,5-difluorobenzamide
DK3029039T3 (en) 2010-05-17 2017-12-04 Forum Pharmaceuticals Inc PHARMACEUTICAL FORMS CONTAINING CRYSTALLINIC FORMS OF (R) -7-CHLOR-N- (QUINUCLIDIN-3-YL) BENZO (B) THIOPHEN-2-CARBOXAMIDE HYDROCHLORIDE MONOHYDRATE
GB201111704D0 (en) 2011-07-07 2011-08-24 Takeda Pharmaceutical Novel compounds
GB201111705D0 (en) 2011-07-07 2011-08-24 Takeda Pharmaceutical Compounds and their use
JO3115B1 (ar) 2011-08-22 2017-09-20 Takeda Pharmaceuticals Co مركبات بيريدازينون واستخدامها كمثبطات daao
CA2872005A1 (en) 2012-05-08 2013-11-14 Forum Pharmaceuticals, Inc. Methods of maintaining, treating or improving cognitive function
GB201209587D0 (en) 2012-05-30 2012-07-11 Takeda Pharmaceutical Therapeutic compounds
ES2694299T3 (es) 2013-02-07 2018-12-19 Heptares Therapeutics Limited Carboxilatos de piperidin-1-ilo y azepin-1-ilo como agonistas del receptor muscarínico M4
WO2014202999A1 (en) 2013-06-21 2014-12-24 Takeda Cambridge Limited 1-sulfonyl piperidine derivatives as modulators of prokineticin receptors
GB201314286D0 (en) 2013-08-08 2013-09-25 Takeda Pharmaceutical Therapeutic Compounds
GB201318222D0 (en) 2013-10-15 2013-11-27 Takeda Pharmaceutical Novel compounds
GB201320905D0 (en) 2013-11-27 2014-01-08 Takeda Pharmaceutical Therapeutic compounds
TW201613864A (en) 2014-02-20 2016-04-16 Takeda Pharmaceutical Novel compounds
GB201616839D0 (en) 2016-10-04 2016-11-16 Takeda Pharmaceutical Company Limited Therapeutic compounds
GB201619514D0 (en) 2016-11-18 2017-01-04 Takeda Pharmaceuticals Co Novel compounds
JP2021138648A (ja) 2020-03-04 2021-09-16 武田薬品工業株式会社 経口固形製剤

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2289578A1 (en) * 1997-05-30 1998-12-03 Neurosearch A/S Spiro-quinuclidine derivatives, their preparation and use
AR013184A1 (es) * 1997-07-18 2000-12-13 Astrazeneca Ab Aminas heterociclicas espiroazobiciclicas, composicion farmaceutica, uso de dichas aminas para preparar medicamentos y metodo de tratamiento o profilaxis
SE9900100D0 (sv) * 1999-01-15 1999-01-15 Astra Ab New compounds

Also Published As

Publication number Publication date
PT1397366E (pt) 2007-04-30
SI1397366T1 (sl) 2007-06-30
CN1512995A (zh) 2004-07-14
NZ529426A (en) 2005-07-29
DE60218032D1 (de) 2007-03-22
EP1397366B1 (en) 2007-02-07
DE60218032T2 (de) 2007-08-16
DK1397366T3 (da) 2007-05-07
CN1294136C (zh) 2007-01-10
WO2002096912A1 (en) 2002-12-05
EP1397366A1 (en) 2004-03-17
ATE353332T1 (de) 2007-02-15
ZA200308779B (en) 2005-02-11
HK1063787A1 (en) 2005-01-14
CA2455341A1 (en) 2002-12-05
NO20035333D0 (no) 2003-11-28
MXPA03010996A (es) 2004-02-27
IL158735A0 (en) 2004-05-12
KR20040003021A (ko) 2004-01-07
BR0210075A (pt) 2004-08-17
ES2280538T3 (es) 2007-09-16

Similar Documents

Publication Publication Date Title
JP2004532877A (ja) 治療に有効なニコチン性アセチルコリン受容体に対する新規なリガンド
EP1213291B1 (en) Spiro [1-azabicyclo[2.2.2]octane-3,2'(3'H)-furo[2,3-b]pyridine for use in the treatment of psychotic and intellectual impairment disorders
US7417049B2 (en) Furyl compounds
US7067515B2 (en) Quinuclidines-substituted-multi-cyclic-heteroaryls for the treatment of disease
EP1425286B1 (en) Substituted 7-aza-[2.2.1]bicycloheptanes for the treatment of diseases
EP0777671B1 (en) Spiro-azabicyclic compounds useful in therapy
US7417050B2 (en) Heterocyclic compounds
US20050250802A1 (en) Novel substituted amines of spirofuropyridines useful in therapy
US6569865B2 (en) Spiro 1-azabicyclo[2.2.2]octane-3,2′(3′h)-furo[2,3-b]pyridine
WO2003087103A1 (en) Thienyl compounds
US7544693B2 (en) Spirofuropyridine aryl derivatives
US7384954B2 (en) 4-substituted imidazoles
US20070191422A1 (en) Nicotinic acetylcholine receptor ligands
US20070244097A1 (en) Nicotinic AcetylcholineReceptor Ligands
AU2002303064A1 (en) Novel ligand for nicotinic acetylcholine receptors useful in therapy
HK1063787B (en) Novel ligand for nicotinic acetylcholine receptors useful in therapy
US20080188518A1 (en) 5-Substituted Imidazoles

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20050525

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20050525

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20090224

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20090721